COMMUNIQUÉS West-GlobeNewswire

-
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results
20/03/2025 -
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
20/03/2025 -
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
20/03/2025 -
Spectral AI Announces Public Filing of Registration Statement for Proposed Initial Public Offering of Spectral IP
20/03/2025 -
Take the Lead: Forward a New Evolution in Slide-Free Pathology with MUSE Microscopy’s Groundbreaking SmartPath Technology
20/03/2025 -
Teclison, Inc. to Participate in Upcoming Investor Conference
20/03/2025 -
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
20/03/2025 -
Cylinder acquires Dieta Health, AI-powered stool imaging technology, to advance AI-driven digestive care
20/03/2025 -
PathAI Announces EMA Qualification for AIM-MASH AI Assist, a Groundbreaking AI Tool for MASH Clinical Trials
20/03/2025 -
WAKE RADIOLOGY'S NEWEST MOBILE MRI UNIT IS NOW ON THE ROAD, PROVIDING GREATER ACCESS TO THE COMMUNITIES THEY SERVE WHILE DELIVERING THE LATEST IN CUTTING-EDGE TECHNOLOGY ACROSS THE TRIANGLE AREA
20/03/2025 -
Rentschler Biopharma appoints Robert Panting as VP Global Client Program Management and Strategy
20/03/2025 -
U.S. Oral Surgery Management Enters Wisconsin Market
20/03/2025 -
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
20/03/2025 -
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
20/03/2025 -
Transporting Sterile Medical Devices – AAMI Sterilization Guidance
20/03/2025 -
Precision Medicine Surge: KFSHRC Achieves 39% Rise in Genetic Mutation Analysis
20/03/2025 -
Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025
20/03/2025 -
Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors
20/03/2025 -
Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease
20/03/2025
Pages